PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32705209-0	2020	Montelukast improves bronchopulmonary dysplasia by inhibiting epithelial-mesenchymal transition via inactivating the TGF-beta1/Smads signaling pathway.	montelukast	0-11	transforming growth factor, beta 1	Rattus norvegicus	117-126	
32705209-8	2020	In addition, MK reduced the expression of Col I, MMP1, MMP3, TGF-beta1 and Smad3 in the lung tissues of the rat model of BPD, as well as in TGF-beta1- and hyperoxia-induced AEC II cells.	montelukast	13-15	transforming growth factor, beta 1	Rattus norvegicus	61-70	
32705209-8	2020	In addition, MK reduced the expression of Col I, MMP1, MMP3, TGF-beta1 and Smad3 in the lung tissues of the rat model of BPD, as well as in TGF-beta1- and hyperoxia-induced AEC II cells.	montelukast	13-15	transforming growth factor, beta 1	Rattus norvegicus	140-149	
32705209-9	2020	The present study demonstrated that MK improved BPD by inhibiting epithelial-mesenchymal transition via inactivating the TGF-beta1/Smads signaling pathway.	montelukast	36-38	transforming growth factor, beta 1	Rattus norvegicus	121-130	
22734808-9	2012	RESULTS: TGF-beta 1-induced astrocyte migration was potentiated by LTD4, but attenuated by the 5-LOX inhibitor zileuton and the CysLT1R antagonist montelukast.	montelukast	147-158	transforming growth factor, beta 1	Rattus norvegicus	9-19